CN101052316A - 包含脂肪掺合物的营养品 - Google Patents
包含脂肪掺合物的营养品 Download PDFInfo
- Publication number
- CN101052316A CN101052316A CNA2005800374672A CN200580037467A CN101052316A CN 101052316 A CN101052316 A CN 101052316A CN A2005800374672 A CNA2005800374672 A CN A2005800374672A CN 200580037467 A CN200580037467 A CN 200580037467A CN 101052316 A CN101052316 A CN 101052316A
- Authority
- CN
- China
- Prior art keywords
- dha
- composition
- dpan
- lipid
- gross weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 9
- 230000035764 nutrition Effects 0.000 title description 2
- 150000002632 lipids Chemical class 0.000 claims abstract description 69
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 68
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 44
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 44
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 44
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 230000035935 pregnancy Effects 0.000 claims abstract description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 11
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 9
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 54
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 27
- 235000021342 arachidonic acid Nutrition 0.000 claims description 27
- 229940114079 arachidonic acid Drugs 0.000 claims description 27
- 235000020778 linoleic acid Nutrition 0.000 claims description 25
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 15
- 150000004665 fatty acids Chemical group 0.000 claims description 14
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 10
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000021290 n-3 DPA Nutrition 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 10
- 229960004232 linoleic acid Drugs 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 125000003835 nucleoside group Chemical group 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 235000021324 borage oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 239000010499 rapseed oil Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 abstract 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 abstract 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- YUFFSWGQGVEMMI-JLNKQSITSA-M (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC([O-])=O YUFFSWGQGVEMMI-JLNKQSITSA-M 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 34
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 18
- 239000002243 precursor Substances 0.000 description 18
- 229960004488 linolenic acid Drugs 0.000 description 17
- 125000001931 aliphatic group Chemical group 0.000 description 12
- 235000013350 formula milk Nutrition 0.000 description 10
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 9
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 8
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 8
- 229960002733 gamolenic acid Drugs 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 4
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 229920000377 Sinistrin Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- Fats And Perfumes (AREA)
- Dairy Products (AREA)
- Medicinal Preparation (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及长链多不饱和脂肪酸用于制备营养组合物的用途，所述营养组合物用于喂养母亲在怀孕期间患有代谢紊乱的婴儿，并涉及相应的组合物。所述组合物包含n－3多不饱和脂肪酸部分，该部分包含基于所述脂质的总重量的至少0.1wt.％的二十二碳六烯酸(DHA)，基于所述脂质的总重量的至少0.01wt.％的n－3二十二碳五烯酸(DPAn－3)，和基于所述脂质的总重量的至少0.01wt.％的二十碳五烯酸(EPA)，其中DHA、DPAn－3和EPA的总和低于总脂质的1wt.％。
Description
技术领域
本发明涉及用于喂养母亲在怀孕期间患有代谢紊乱的婴儿的长链多不饱和脂肪酸的用途，并涉及具有适于所述用途的多不饱和脂肪酸的营养组合物。
背景技术
婴儿的多不饱和脂肪酸状态在本领域中一直引起人们的兴趣。不同的脂肪酸贡献了数种功能。例如，二十二碳六烯酸(DHA)在大脑的灰质和眼睛的视网膜中都是主要的结构性脂肪酸组分，并因此对大脑和眼睛的功能是必须的。因此，DHA对于生长中的婴儿是特别重要的。
作为DHA缺乏的结果，n-6二十二碳五烯酸(DPA n-6)被替代掺入到婴儿生长中的大脑中。这是不希望的，因为它难于逆转并可导致神经发育损坏。另外，DHA不足可导致健康发育障碍。
DHA缺乏对于母亲在怀孕期间患有疾病的婴儿是特别重要的。因此，特别是对于这些婴儿，婴儿代乳品提供在婴儿中最佳的的脂肪酸分布是至关重要的。
DE 4 327 310描述了得自奶牛的包含二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)和n-3二十二碳五烯酸(DPA-n3)的牛奶组合物，其在儿童中用于促进生长、智力功能和视力功能。然而，所述脂肪组合物不适合于喂养给婴儿，因为亚油酸/α-亚麻酸(LA/ALA)的重量比不是最优化的。
WO 01/78530描述了包含确定量的二十二碳六烯酸(DHA)和花生四烯酸(AA)以及它们的前体关键脂肪酸ALA和LA的营养组合物，其用于提供营养和用于增强早产儿的神经发育。
WO 2004/052115描述了甘油酯组合物，制备该甘油酯组合物的方法和包含该甘油酯组合物的营养制剂。所述甘油酯组合物主要包含带有一个或多个长链多不饱和脂肪酸的甘油单酯和甘油二酯。还公开了使用所述甘油酯组合物和营养制剂的方法。
WO 98/36745公开了用于降低新生儿坏死性小肠结肠炎的发病率的方法和组合物。所述的组合物提供n-6和n-3长链多不饱和脂肪酸。
本发明的目的就是提供具有多不饱和脂肪酸的营养组合物，其适合于喂养母亲在怀孕期间患有代谢紊乱的婴儿
发明内容
本发明的发明人相信在婴儿代乳品(infant formula)代乳品中不仅需要丰富地存在DHA和AA用于使大脑发育最优化，而且这些脂肪酸的前体也是关键的，因为所述DHA和AA的重要部分由其前体在大脑中局部合成。因此，本发明的发明人相信仅向标准婴儿代乳品中加入DHA和/或AA不足以在多种神经组织中提供DHA的最佳掺入。因此，本发明的组合物除了DHA和AA之外，还包括相当量的DHA和AA的前体。
为了最佳的从头合成，本发明的组合物包含DHA的前体，该前体至少包括α-亚麻酸(ALA)、二十碳五烯酸(EPA)和n-3二十二碳五烯酸(DPA-n3)。然而，在所述组合物中不能以高的量包括EPA，因为EPA抑制亚麻酸(LA)向另一种重要的脂肪酸AA的代谢转化。在本发明组合物中，相对低的EPA的量由相对高量的二十二碳五烯酸(DPAn-3)补偿。两种前体都是关键的，因为相信它们提供了刺激局部DHA合成的前体。
因此，在最佳的配置中，
在本发明组合物中的EPA/DHA重量比为0.05--1，这与人奶的平均比例相近或略低；
为了提供足够的DHA前体，每个DHA的长链DHA前体[DPAn-3+EPA]的重量比优选为0.25--；和
本发明组合物的DPA-n3/EPA重量比为0.25--5。人奶通常具有大于约1的DPA-n3/EPA重量比。
可适当使用的高DPAn-3油，包括海洋生物油(marine oils)，如海豹油和富含DPAn-3的鱼油。虽然本发明的组合物具有2--25的DHA/DPAn-3重量比，仅稍大于在人奶中的DHA/DPAn-3平均含量重量比，但它是对于可获得的不包含或仅包含痕量的DPA-n3的婴儿代乳品的主要改进。
为了进一步改进所述组合物，将ALA以相当的量加入以进一步降低DHA的不足。在本发明的组合物中ALA/DHA的比例优选为5--25。
另外，在本发明的组合物中包括花生四烯酸(AA)是非常重要的，特别在那些包含二十二碳六烯酸的长链前体的组合物中。AA是衍生自亚油酸的ω-6-脂肪酸，并主要存在于如肉、蛋和奶等食物来源中。AA包含20个碳原子和4个双键(20:4n-6)，并且是在大脑中发现的主要ω-6-脂肪酸。除了AA之外，所述脂质包含相当量的AA前体，即γ-亚麻酸(GLA)和亚油酸(LA)也是非常重要的。这些脂肪酸提供用于局部合成AA的前体。因为本发明的组合物具有高的GLA含量，即基于所述脂质的总重量优选0.05--0.4wt.％的GLA，本发明的组合物具有低的亚油酸含量，即基于所述脂质的总重量的10-15wt.％的LA。
具体实施方式
本发明提供营养组合物，其中糖提供40-75％的总卡路里，脂质提供20-50％的总卡路里和蛋白质提供5-12.5％的总卡路里，其中所述脂质包含至少一种植物脂质源和包含n-3二十二碳五烯酸(DPAn-3)的脂质源，所述脂质包含n-3多不饱和脂肪酸部分和n-6多不饱和脂肪酸部分，其中：
所述n-3多不饱和脂肪酸部分包含
基于所述脂质的总重量的至少0.1wt％的二十二碳六烯酸(DHA)；基于所述脂质的总重量的至少0.01wt％DPAn-3；基于所述脂质的总重量的至少0.01wt.％的二十碳五烯酸(EPA)；其中DHA、DPAn-3和EPA的总量低于总脂质的1wt.％；和基于所述脂质的总重量的1.9-3wt.％的α亚油酸(ALA)；以及重量比例：EPA/DHA的比例为0.05-1；(DPAn-3+EPA)/DHA为0.25-1；DPAn-3/EPA为0.25-5；DHA/DPAn-3为2-25；ALA/DHA为5-25，
所述n-6多不饱和脂肪酸部分包含
基于所述脂质的总重量的0.2-1wt.％的花生四烯酸(AA)；和基于所述脂质的总重量的10-15wt.％的亚油酸(LA)；和
LA/ALA的重量比为5-10。
被视为包含脂质掺混物的营养品的本发明组合物可适用于喂养健康婴儿并特别适用于喂养母亲在怀孕期间患有代谢紊乱的婴儿。如上所述的n-3多不饱和脂肪酸部分对于这些婴儿提供重要的益处。最优化地，如上所述的组合物包含如本文中所述的n-3多不饱和脂肪酸部分和n-6多不饱和脂肪酸部分二者。
在本发明的另一个方面中提供长链多不饱和脂肪酸用于制备营养组合物的用途，所述营养组合物优选为液体组合物，用于喂养在母亲怀孕期间患有代谢紊乱的婴儿，所述组合物包含基于所述脂质的总重量的至少0.1wt.％的二十二碳六烯酸(DHA)；和基于所述脂质的总重量的至少0.01wt.％的n-3二十二碳五烯酸(DPAn-3)；和基于所述脂质的总重量的至少0.01wt.％的二十碳五烯酸(EPA，n3)；并且其中DHA、DPAn-3和EPA的总和低于总脂质的1wt.％。所述营养组合物可具有任何希望的和/或适用于喂养目的形式，并优选为液体形式。
本发明的组合物特别适用于母亲在怀孕期间患有I型糖尿病、II型糖尿病、过重和肥胖中的一种或多种的婴儿。这些代谢紊乱是母亲向婴儿传送DHA和/或DHA前体降低的具体原因并可导致增多的DPAn-6掺入到脑膜中。
n-3多不饱和脂肪酸部分：
ω3(n-3)脂肪酸的缩写：ALA＝C18:3n-3＝α-亚麻酸；EPA＝20:5n-3＝二十碳五烯酸；DPAn-3＝22:5n-3＝n-3二十二碳五烯酸；DHA＝22:6n-3＝二十二碳六烯酸。
本发明的组合物包含n-3多不饱和脂肪酸部分，该部分包含基于所述脂质总重量的至少0.1wt％，优选0.10-1wt％，更优选0.15-0.5wt％的DHA。本发明的组合物包含基于所述脂质总重量的至少0.01wt％，优选0.015-0.5wt％的DPAn-3。所述EPA的含量基于所述脂质总重量为至少0.01wt％，优选0.03-0.5wt％，甚至更优选0.04-0.1wt％。
在本发明组合物中DHA，DPA和EPA的累积重量％(总和)为低于总脂质的1wt.％，优选低于0.5wt.％。
本发明的组合物的重量比EPA/DHA为0.05-1，优选0.1-0.5，更优选0.2-0.5。本发明的组合物的重量比DHA/DPAn-3为2-25，优选5-15。本发明的组合物的重量比(DPAn-3+EPA)/DHA为0.25-1。更优化地，重量比(DHA前体/DHA)，即(DPAn-3+EPA)/DHA为0.3-0.5。在母乳中，重量比DPAn-3/EPA通常大于1。本发明的组合物的重量比DPAn-3/EPA优选为0.25-5，更优选0.3-3。特别富含DPAn-3的鱼油，选择的海豹油和生物技术制造的高DPAn-3油可适用于制备本发明的组合物。
本发明的组合物包含基于所述脂质总重量的1.9-3wt.％，优选2-2.5wt.％的ALA。ALA的wt.％比母乳略高。母乳通常包含基于所述脂质总重量的约0.5-1.6wt.％的ALA。然而，母乳通常包含增加的重量百分比的长链的DHA前体，例如DPAn3和EPA。因此，在本发明组合物中ALA/DHA的重量比比母乳高，即，在本发明组合物中为5-25，与母乳中的约2相对。优选在本发明组合物中ALA/DHA比例为7.5-15。
n-6多不饱和脂肪酸部分：
ω6(n-6)脂肪酸的缩写：LA＝18:2n-6＝亚油酸；GLA＝18:3n-6＝γ-亚麻酸；DGLA＝20:3n-6＝二高-γ-亚麻酸；AA＝20:4n-6＝花生四烯酸；DPAn-6＝22:5n-6＝n-6二十二碳五烯酸。
本发明的组合物包含基于所述脂质总重量的0.2-1wt％，优选0.25-0.75wt％的AA。AA不能以高的量掺入到所述组合物中，因为它的促炎作用。因此，作为AA的前体，本发明的组合物优选包含基于所述脂质总重量的0.05-1wt％，优选0.1-0.4wt％，更优选0.15-0.3wt％的GLA。本发明的组合物包含高含量的GLA以至少部分补偿本发明组合物中相对于母乳降低的DGLA的量。由于前体的累计量仍相对低，本发明的组合物包含高量的LA，即基于所述脂质总重量的为10-15wt％，优选11-14wt％的LA，其比在人乳中的LA平均含量约为9wt％略高(Luukainen等人，Eur J Pediatr(1995)154：316-319)。然而，掺入现存量的GLA和最佳的n-3多不饱和脂肪酸部分不需要在本发明组合中包含过量的LA，即，基于总脂质大于15wt.％的LA
在本发明组合物中重量比LA/ALA为5-10。
婴儿营养品：
本发明涉及适合于喂养婴儿的营养代乳品(nutritional formula)代乳品，即其中糖提供40-75％，脂质提供20-50％和蛋白质提供5-12.5％的总卡路里的营养组合物。优选蛋白质提供7.5-12.5％的总卡路里。
本发明组合物包含至少一种植物性脂质源和包含DPAn-3的脂质源。更优选，本发明的组合物包含选自月见草油、琉璃苣油和黑加仑籽油中的至少一种脂质源；选自低芥酸菜子油(canola oil)、葵花籽油、椰子油、棕榈油和豆油中的至少一种脂质源；和至少一种含DPAn-3的脂质源。在另外优选的实施方案中，本发明的组合物还包含真菌的油。含DPAn-3的脂质源，基于含DPAn-3的脂肪酸的脂质源，优选包含至少1wt％，甚至更优选至少2wt％的DPA n-3。为了易于制造，含DPAn-3的脂质源，基于含DPAn-3的脂肪酸的脂质源，包含至少15wt％，更优选至少20wt％的DHA，甚至更优选至少25wt％的DHA。
在本发明的另外的方面提供通过给食本发明的组合物治疗母亲在怀孕期间患有代谢紊乱的婴儿的方法。
为了制备本发明的组合物，使用动物和植物脂质源的掺混物。由于脂质源的脂肪酸组成可显著不同(即使获得自相同的植物和动物来源)，因此最好首先分析待应用的脂质源并且然后计算获得本发明组合物需要的单独油的量并混合所述脂质源。或者，本领域技术人员可在适当的手册中发现合适的脂质源。所用的脂质源优选为非人源的。本发明中所述的脂肪酸可提供为游离脂肪酸，以三甘油酯的形式，以磷脂的形式，或作为上述一种或多种的混合物。
本发明组合物的糖优选主要由乳糖提供，因为它是最适合于喂养婴儿的。因此，所述可消化的糖部分(糖)优选包含基于所述糖部分总重量的至少50wt.％，更优选至少90wt.％的乳糖。
睡眠对于婴儿正常的智力发育也是极其重要的。因此，婴儿优选具有降低的肠道不适。水溶性不可消化的纤维降低肠道不适如气胀的发生。因此，本发明的组合物优选还包含每100kcal本发明的组合物0.2-5克的水溶性不可消化的纤维，更优选每100kcal 0.5-1.5克。优选本发明的组合物包含至少一种选自低聚半乳醣、低聚果糖和菊糖的水溶性不可消化的纤维。
对于婴孩来说生命的头几个月最佳的大脑发育是特别重要的。因此，本发明特别涉及营养代乳品，其最佳适用于在生命的头几个月中喂养。据信0.600-0.800kcal/ml的含热量在这些年幼的婴儿中降低了肠道不适，从而刺激脂肪酸的吸收。因此，本发明的组合物优选包含0.600-0.800kcal/ml，更优选0.650-0.680kcal/ml。
由于母亲在怀孕期间患有疾病的婴儿有时必须赶上神经组织发育，因此本发明优选包含核苷酸。本发明的组合物优选还包含每100kcal 2-25mg的核苷酸和/或2-25mg的核苷，更优选每100kcal 3-10mg的核苷酸。本发明的组合物优选包含选自胞苷-5-单磷酸酯、尿苷-5-单磷酸酯、腺苷-5-单磷酸酯、鸟苷-5-单磷酸酯和肌苷-5-单磷酸酯中的至少2种核苷酸。所述核苷酸和/或核苷还与本发明组合物的其它成分协同起作用刺激免疫系统。
实施例
实施例1：婴儿代乳品：
液体婴儿营养品，通过将13.9g粉末与水混合形成100ml终产品，所述液体产品每100ml包含：
能量：66kcal
蛋白质：8en％
可消化糖类：44en％(包含7.3g乳糖)
脂质：48en％(包含：基于所述脂质总重量的0.2wt.％的DHA；0.02wt.％的DPAn-3；0.05wt.％的EPA；2.2wt.％的ALA，0.2wt.％的GLA；0.35wt.％的AA，13wt.％的LA)
纤维：0.8g(包含0.05g多聚果糖(Raftiline HpTM，Orafti，Tienen，Belgium)；0.55g低聚转半乳糖(Vivinal-GOSTM(Borculo DomoIngredients，Netherlands)；0.20g如在EP1373543实施例1中所述制备的果胶水解产物。
核苷酸：0.89mg胞苷-5-单磷酸酯；
0.55mg尿苷-5-单磷酸酯；
0.82mg腺苷-5-单磷酸酯；
0.20mg鸟苷-5-单磷酸酯；
0.34mg肌苷-5-单磷酸酯。
摩尔渗透压浓度：300mOsmol/l
所述组合物还包含符合婴儿代乳品的国际指导原则的量的胆碱(6mg/100ml)和牛磺酸(6.3mg/100ml)；无机和微量元素(包括2mg锌/100ml)和维生素。
Claims (12)
1.长链多不饱和脂肪酸用于制备液体营养组合物的用途，所述营养组合物用于喂养母亲在怀孕期间患有代谢紊乱的婴儿，所述组合物包含n-3多不饱和脂肪酸部分，该部分包含基于所述脂质总重量的至少0.1wt.％的二十二碳六烯酸(DHA)，基于所述脂质总重量的至少0.01wt.％的n-3二十二碳五烯酸(DPAn-3)，和基于所述脂质总重量的至少0.01wt.％的二十碳五烯酸(EPA)，其中DHA、DPAn-3和EPA的总和低于总脂质的1wt.％。
2.根据权利要求1的用途，其中所述重量比：
-EPA/DHA比为0.05-1；
-(DPAn-3+EPA)/DHA为0.25-1；
-DPAn-3/EPA为0.25-5；和
-DHA/DPAn-3为2-25。
3.根据权利要求1或2的用途，其中所述的组合物还包含n-6多不饱和脂肪酸部分，该部分包含：
-基于所述脂质总重量的0.05-0.4wt.％的GLA；
-基于所述脂质总重量的0.2-1wt.％的花生四烯酸(AA)；和
-基于所述脂质总重量的10-15wt.％的亚油酸(LA)。
4.根据权利要求1-3中任一项的用途，其中所述的母亲在怀孕期间患有I型糖尿病、II型糖尿病、肥胖或过重。
5.营养组合物，其中糖提供40-75％的总卡路里，脂质提供20-50％的总卡路里和蛋白质提供5-12.5％的总卡路里，其中所述脂质包含至少一种植物脂质源和含n-3二十二碳五烯酸(DPAn-3)的脂质源，所述脂质包含n-3多不饱和脂肪酸部分和n-6多不饱和脂肪酸部分，其中：
a.所述n-3多不饱和脂肪酸部分包含
-基于所述脂质总重量的至少0.1wt.％的二十二碳六烯酸(DHA)；基于所述脂质总重量的至少0.01wt.％的DPAn-3；基于所述脂质总重量的至少0.01wt.％的二十碳五烯酸(EPA)；其中DHA、DPAn-3和EPA的总和低于总脂质的1wt.％；和
-基于所述脂质总重量的1.9-3wt.％的α-亚油酸(ALA)；和
-所述重量比；
-EPA/DHA比为0.05-1；
-(DPAn-3+EPA)/DHA为0.25-1；
-DPAn-3/EPA为0.25-5；
-DHA/DPAn-3为2-25；和
-ALA/DHA为5-25；和
b.所述n-6多不饱和脂肪酸部分包含
-基于所述脂质总重量的0.2-1wt.％的花生四烯酸(AA)；和
-基于所述脂质总重量的10-15wt.％的亚油酸(LA)；
c.重量比LA/ALA为5-10。
6.根据权利要求5的组合物，其热量密度为0.65-0.80千卡/毫升。
7.根据权利要求5或6的组合物，其包含选自月见草油、琉璃苣油和黑加仑籽油中的至少一种脂质源；选自低芥酸菜子油、葵花籽油、椰子油、棕榈油和豆油中的至少一种脂质源；和至少一种含DPAn-3的脂质源。
8.根据权利要求5-7中任一项的组合物，其包含基于所述糖部分总重量的至少50wt.％的乳糖。
9.根据权利要求5-8中任一项的组合物，其每100kcal包含2-25mg的核苷酸和/或2-25mg的核苷。
10根据权利要求5-9中任一项的组合物，其每100kcal包含0.2-5克的水溶性不可消化的纤维。
11.根据前述权利要求中任一项的组合物，其包含基于所述脂质总重量的0.05-0.4wt.％的γ亚麻酸(GLA)。
12.通过给药如权利要求1-11中任一项所述的组合物而治疗母亲在怀孕期间患有代谢紊乱的婴儿的方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04026825A EP1656839A1 (en) | 2004-11-11 | 2004-11-11 | Nutrition containing lipid blend |
| EP04026825.2 | 2004-11-11 | ||
| PCT/EP2005/012122 WO2006050975A1 (en) | 2004-11-11 | 2005-11-11 | Nutrition containing fat blend |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210004226.XA Division CN102511818B (zh) | 2004-11-11 | 2005-11-11 | 包含脂肪掺合物的营养品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101052316A true CN101052316A (zh) | 2007-10-10 |
| CN101052316B CN101052316B (zh) | 2012-02-22 |
Family
ID=34927339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210004226.XA Expired - Fee Related CN102511818B (zh) | 2004-11-11 | 2005-11-11 | 包含脂肪掺合物的营养品 |
| CN2005800374672A Expired - Fee Related CN101052316B (zh) | 2004-11-11 | 2005-11-11 | 包含脂肪掺合物的营养品 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210004226.XA Expired - Fee Related CN102511818B (zh) | 2004-11-11 | 2005-11-11 | 包含脂肪掺合物的营养品 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8053471B2 (zh) |
| EP (3) | EP1656839A1 (zh) |
| JP (1) | JP2008519796A (zh) |
| CN (2) | CN102511818B (zh) |
| AT (1) | ATE457656T1 (zh) |
| AU (1) | AU2005303903B2 (zh) |
| BR (1) | BRPI0517479B1 (zh) |
| CA (1) | CA2586946C (zh) |
| DE (1) | DE602005019452D1 (zh) |
| DK (1) | DK1809125T3 (zh) |
| ES (1) | ES2341355T3 (zh) |
| NZ (1) | NZ554629A (zh) |
| PL (1) | PL1809125T3 (zh) |
| PT (1) | PT1809125E (zh) |
| RU (1) | RU2402927C2 (zh) |
| SG (1) | SG143274A1 (zh) |
| UA (1) | UA89207C2 (zh) |
| WO (1) | WO2006050975A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104114043A (zh) * | 2011-12-27 | 2014-10-22 | 雅培制药有限公司 | 含有核苷酸和/或类胡萝卜素的降低卡路里的婴儿配方用于降低生命后期的不利健康影响的用途 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
| PL1888081T3 (pl) | 2005-05-23 | 2017-07-31 | Massachusetts Institute Of Technology | Kompozycje zawierające PUFA i sposoby ich zastosowania |
| WO2007058523A1 (en) * | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
| WO2008054192A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
| AU2006327995B2 (en) * | 2005-12-23 | 2012-09-13 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
| WO2008054193A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Nutritional products that comprise saccharide oligomers |
| WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009002146A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| US20100331258A1 (en) | 2007-06-26 | 2010-12-30 | N.V. Nutricia | memory in subjects with mini-mental state examination of 24-26 |
| WO2009082203A1 (en) | 2007-12-20 | 2009-07-02 | N.V. Nutricia | Liquid nucleotides/nucleosides-containing product |
| CN100542411C (zh) * | 2007-09-24 | 2009-09-23 | 张国浩 | 一种含ω-3多不饱和脂肪酸的营养均衡调和油及其生产方法 |
| US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
| US9149452B2 (en) * | 2009-04-20 | 2015-10-06 | Women's & Children's Health Research Institute Inc. | Methods and compositions for promoting the neurological development of an infant |
| JP5335601B2 (ja) * | 2009-07-30 | 2013-11-06 | ビーンスターク・スノー株式会社 | 栄養組成物 |
| WO2012087113A1 (en) * | 2010-12-24 | 2012-06-28 | N.V. Nutricia | Improved nutritional tablet |
| AU2013277441B2 (en) | 2012-06-17 | 2017-07-06 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
| EP2968246A4 (en) * | 2013-03-13 | 2016-08-03 | Matinas Biopharma Inc | OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE |
| US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| FR3045069B1 (fr) | 2015-12-14 | 2019-01-25 | Metabolium | Procede d'enrichissement de protistes en lipides riches en acides gras polyinsatures, plus particulierement de classe omega 3, et sa mise en oeuvre pour la production de ces lipides |
| BR112018071493A2 (pt) * | 2016-04-18 | 2019-02-19 | N.V. Nutricia | usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce |
| WO2019040938A1 (en) * | 2017-08-25 | 2019-02-28 | Struct Nutrition, Llc | COMPOSITIONS AND METHODS FOR PREVENTING, RELIEVING AND TREATING NEUROLOGICAL INJURY FOLLOWING SKIN TRAUMA |
| WO2023232882A1 (en) | 2022-05-31 | 2023-12-07 | N.V. Nutricia | Infant formula for improving cognitive development |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670285A (en) * | 1982-08-06 | 1987-06-02 | The University Of Toronto Innovations Foundation | Infant formula |
| ES2033193B1 (es) * | 1990-10-30 | 1994-01-16 | Ganadera Union Ind Agro | Mezcla grasa para nutricion infantil y de adultos. |
| KR940003473A (ko) | 1992-08-14 | 1994-03-12 | 이순목 | n-3 지방산이 축적된 우유 및 우유용 사료조성물 |
| NL9401644A (nl) * | 1994-10-06 | 1996-05-01 | Friesland Brands Bv | Voedingsmiddel voor zwangere en lacterende vrouwen |
| WO1996033263A1 (fr) * | 1995-04-17 | 1996-10-24 | JAPAN, represented by DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY | Nouveaux micro-organismes capables de produire des acides gras hautement insatures et procede de production d'acides gras hautement insatures utilisant ces micro-organismes |
| ATE303726T1 (de) * | 1995-05-30 | 2005-09-15 | Suntory Ltd | Hühnereier mit einem hohen anteil an mehrfach ungesättigten fettsäuren, verfahren für deren herstellung und die verwendung derselben |
| ATE221324T1 (de) * | 1996-11-20 | 2002-08-15 | Nutricia Nv | Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms |
| ES2219871T3 (es) * | 1997-02-21 | 2004-12-01 | Abbott Laboratories | Procedimiento y composiciones que sirven para limitar la frecuencia de la enterocolitis necrotizante del recien nacido. |
| CN1660065A (zh) * | 1997-03-27 | 2005-08-31 | 布里斯托尔-迈尔斯斯奎布公司 | 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途 |
| US6432684B1 (en) * | 1997-04-11 | 2002-08-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
| AU6503699A (en) * | 1998-10-05 | 2000-04-26 | Abbott Laboratories | Altered fatty acid biosynthesis in insect cells using delta five desaturase |
| US6495599B2 (en) * | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
| ITBO20000471A1 (it) | 2000-07-31 | 2002-01-31 | Vieri Ridolfi | Dispositivo di supporto per prodotti da fumo particolarmente sigarette . |
| DE10057976B4 (de) | 2000-11-22 | 2005-02-03 | Südzucker AG Mannheim/Ochsenfurt | Verfahren zur Herstellung von Pektinhydrolyseprodukten |
| AU2002309856B2 (en) * | 2001-05-14 | 2008-10-23 | Dsm Ip Assets B.V. | Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| US20040209953A1 (en) * | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
| GB0308104D0 (en) * | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
| EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
-
2004
- 2004-11-11 EP EP04026825A patent/EP1656839A1/en not_active Withdrawn
-
2005
- 2005-11-11 JP JP2007540596A patent/JP2008519796A/ja active Pending
- 2005-11-11 PT PT05813382T patent/PT1809125E/pt unknown
- 2005-11-11 AU AU2005303903A patent/AU2005303903B2/en not_active Ceased
- 2005-11-11 UA UAA200706381A patent/UA89207C2/ru unknown
- 2005-11-11 SG SG200803936-4A patent/SG143274A1/en unknown
- 2005-11-11 DE DE602005019452T patent/DE602005019452D1/de active Active
- 2005-11-11 CN CN201210004226.XA patent/CN102511818B/zh not_active Expired - Fee Related
- 2005-11-11 EP EP10153682A patent/EP2191733A1/en not_active Withdrawn
- 2005-11-11 CA CA2586946A patent/CA2586946C/en not_active Expired - Fee Related
- 2005-11-11 AT AT05813382T patent/ATE457656T1/de active
- 2005-11-11 ES ES05813382T patent/ES2341355T3/es active Active
- 2005-11-11 RU RU2007121665/13A patent/RU2402927C2/ru not_active IP Right Cessation
- 2005-11-11 DK DK05813382.8T patent/DK1809125T3/da active
- 2005-11-11 WO PCT/EP2005/012122 patent/WO2006050975A1/en active Application Filing
- 2005-11-11 US US11/666,990 patent/US8053471B2/en not_active Expired - Fee Related
- 2005-11-11 BR BRPI0517479-1A patent/BRPI0517479B1/pt not_active IP Right Cessation
- 2005-11-11 CN CN2005800374672A patent/CN101052316B/zh not_active Expired - Fee Related
- 2005-11-11 EP EP05813382A patent/EP1809125B1/en not_active Not-in-force
- 2005-11-11 NZ NZ554629A patent/NZ554629A/en not_active IP Right Cessation
- 2005-11-11 PL PL05813382T patent/PL1809125T3/pl unknown
-
2011
- 2011-10-03 US US13/251,399 patent/US8729123B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104114043A (zh) * | 2011-12-27 | 2014-10-22 | 雅培制药有限公司 | 含有核苷酸和/或类胡萝卜素的降低卡路里的婴儿配方用于降低生命后期的不利健康影响的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1809125B1 (en) | 2010-02-17 |
| JP2008519796A (ja) | 2008-06-12 |
| BRPI0517479A (pt) | 2008-10-07 |
| PL1809125T3 (pl) | 2010-07-30 |
| CN102511818B (zh) | 2014-12-24 |
| DE602005019452D1 (de) | 2010-04-01 |
| EP2191733A1 (en) | 2010-06-02 |
| RU2402927C2 (ru) | 2010-11-10 |
| SG143274A1 (en) | 2008-06-27 |
| DK1809125T3 (da) | 2010-06-07 |
| ATE457656T1 (de) | 2010-03-15 |
| AU2005303903A1 (en) | 2006-05-18 |
| US20080269330A1 (en) | 2008-10-30 |
| CN102511818A (zh) | 2012-06-27 |
| RU2007121665A (ru) | 2008-12-20 |
| EP1656839A1 (en) | 2006-05-17 |
| ES2341355T3 (es) | 2010-06-18 |
| WO2006050975A1 (en) | 2006-05-18 |
| CA2586946A1 (en) | 2006-05-18 |
| US20120027885A1 (en) | 2012-02-02 |
| NZ554629A (en) | 2010-09-30 |
| CA2586946C (en) | 2014-09-30 |
| EP1809125A1 (en) | 2007-07-25 |
| US8053471B2 (en) | 2011-11-08 |
| UA89207C2 (ru) | 2010-01-11 |
| US8729123B2 (en) | 2014-05-20 |
| AU2005303903B2 (en) | 2012-05-31 |
| BRPI0517479B1 (pt) | 2015-06-09 |
| PT1809125E (pt) | 2010-05-20 |
| CN101052316B (zh) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101052316B (zh) | 包含脂肪掺合物的营养品 | |
| CN101027074B (zh) | 复合肠内营养组合物 | |
| CN1091363C (zh) | 脂肪掺合物 | |
| CA2147302C (en) | A lipid composition for normalizing injury | |
| US6465666B2 (en) | Isomer enriched CLA compositions | |
| CN1471391A (zh) | 治疗高甘油三酯血症的组合物和方法 | |
| CN1620902A (zh) | 蛋鸡营养饲料 | |
| US6020378A (en) | Method for selectively altering body fat level, feed efficiently, or weight gain | |
| CN1092934A (zh) | 饲喂幼畜的方法和饲喂组合物 | |
| CN1927050A (zh) | Dha微胶囊食品添加剂、dha软胶囊保健品及其应用 | |
| CN1579180A (zh) | 调和红花油 | |
| JPH0551271B2 (zh) | ||
| CN105166415A (zh) | 一种改善猪生长和肠道健康的不同链长脂肪组合物及其应用 | |
| CN108969540A (zh) | 一种用于防治骨关节炎的组合物及其制备方法和应用 | |
| Borghi et al. | Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management | |
| JPS63237745A (ja) | α−リノレン酸系脂肪酸の含有率が高められた動物性食品の生産方法 | |
| US11679091B2 (en) | Lymphatic circulation improving agents | |
| JP2011142855A (ja) | ヒラメ飼育用配合飼料及びヒラメ飼育方法 | |
| Sheppard | Specialty Eggs: n‐3 Fatty Acid‐Enriched Eggs | |
| Zhang et al. | Health Effects of Docosahexanoic Acid (DHA)‒Enriched Eggs | |
| Echols | Using nutritional supplements to manage avian diseases. | |
| Sanders | Potential health benefits of fish oils |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120222 Termination date: 20171111 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |